Znn3bq.jpeg
²é¿´: 1583  |  »Ø¸´: 8
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

mjjnj

ľ³æ (СÓÐÃûÆø)

[½»Á÷] Ò»¾ä»°ÇóÖú¸ßÈË£¡¼±°¡!£¨¹ØÓÚÁÙ´²·½ÃæµÄ£¬Ó¢Ò뺺£©

The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co-primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) patients¡£Sample Text
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

petrocatal

ľ³æ (ÕýʽдÊÖ)

ͨ¹ýÁÙ´²ÁÆÐ§µ÷²é,È·¶¨²¡ÈËÖеÃÒæÓÚÁÙ´²µ¼ÏòÐÔÖÎÁÆÊýÄ¿£¬¿ÉÈ·¶¨Ê×´ÎÁÆÐ§µÄ½ØÖ¹µã¡£
³ÕÃÔ¿ÆÑÐ
2Â¥2010-11-03 13:09:58
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

wust67

½ð³æ (ÖøÃûдÊÖ)

petrocatal   ÍøÓÑ·­ÒëµÃºÜºÃ£¡
3Â¥2010-11-03 13:58:57
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

wust67

½ð³æ (ÖøÃûдÊÖ)

Sample Text ¡ª¡ªÑù¶Î
4Â¥2010-11-03 13:59:43
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

mjjnj

ľ³æ (СÓÐÃûÆø)

petrocatal µÄ·­Ò뻹ÊÇûÄܰÑÒâ˼·­ÒëºÃ£¬²»¹ÜÔõÑù£¬Ö÷ÒªÁÆÐ§ÖÕµãÊÇxxxµÄÁÙ´²Ó¦´ð ÊÇÕû¸ö¾ä×ÓµÄÖ÷¸É  ÆÚ´ý¸ßÊÖ¼ÌÐø·­Ò룬лл£¡
5Â¥2010-11-03 14:05:14
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

petrocatal

ľ³æ (ÕýʽдÊÖ)

ÁÆÐ§¡°Öյ㡱ÊÇ¡°Ó¦´ð¡±»ò·´À¡µÄ¡°·­Ò롱£¬´ÓÖÐÎÄÉϽ²¾Í²»Í¬£¬¿Ï¶¨²»ÄÜÖ±Ò룡Èç´ËÈ·¶¨¾ä×ÓµÄÖ÷¸É£¬·Ç³£±ðŤ¡£¼ò¶øÑÔÖ®£¬ÖÕµãÊÇÓ¦´ð£¿£¿
½¨Ò鏸³öÉÏÏÂÎÄ£¬Õâ¶Î»°¿Ï¶¨ÓÐÏà¹ØµÄÓï¾³£¬ÐèÒª½áºÏÉÏÏÂÎÄ£¡·­Òë¸úÄã×öÔĶÁÀí½âÒ»Ñù£¡
³ÕÃÔ¿ÆÑÐ
6Â¥2010-11-03 15:17:33
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

mjjnj

ľ³æ (СÓÐÃûÆø)

TYGACIL was evaluated in adults for the treatment of complicated skin and skin structure infections (cSSSI) in two randomized, double-blind, active-controlled, multinational, multicenter studies (Studies 300 and 305). These studies compared TYGACIL (100 mg intravenous initial dose followed by 50 mg every 12 hours) with vancomycin (1 g intravenous every 12 hours)/aztreonam (2 g intravenous every 12 hours) for 5 to 14 days. Patients with complicated deep soft tissue infections including wound infections and cellulitis (¡Ý10 cm, requiring surgery/drainage or with complicated underlying disease), major abscesses, infected ulcers, and burns were enrolled in the studies. The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co-primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) patients. See Table 6. Clinical cure rates at TOC by pathogen in the microbiologically evaluable patients are presented in Table 7.
7Â¥2010-11-03 15:24:17
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

petrocatal

ľ³æ (ÕýʽдÊÖ)

ÔÚÁÙ´²ÁÆÐ§ÊµÑéµ÷²éÖУ¬Ö÷ÒªÁÆÐ§µÄÖÕµã¿É¿´×÷ÊÇÔÚÓɾ­ÁÙ´²¸Ä½øµÄµ¼ÏòÐÔÖÎÁƵIJ¡ÈËÓë¿ÉÁÙ´²ÆÀ¼Û²¡È˹¹³ÉµÄÖ÷ÒªÈËȺÖеÄÖÎÁÆÓ¦´ð¡£
population_ÈËȺ£¬ÓÃ×÷¸´Êý£¬Òâζ×Ų¡ÈË·ÖΪÁ½À࣬ÆäËûµÄ·­ÒëÓ¦¸Ã±È½Ï¼òµ¥¡£
³ÕÃÔ¿ÆÑÐ
8Â¥2010-11-03 21:22:52
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

petrocatal

ľ³æ (ÕýʽдÊÖ)

mjjnj(½ð±Ò+50, ·­ÒëEPI+1):лл£¡ 2010-11-04 09:46:01
ÔÚÁÙ´²ÁÆÐ§ÊµÑéµ÷²éÖУ¬Ö÷ÒªÁÆÐ§µÄÖÕµã¿É¿´×÷ÊÇÔÚÓɽÓÊÜÁËÁÙ´²¸Ä½øµÄµ¼ÏòÐÔÖÎÁƵIJ¡ÈËÓë¿ÉÁÙ´²ÆÀ¼ÛµÄ²¡ÈËËù¹¹³ÉµÄÖ÷ÒªÈËȺÖеÄÖÎÁÆÓ¦´ð¡£
population_ÈËȺ£¬ÓÃ×÷¸´Êý£¬Òâζ×Ų¡ÈË·ÖΪÁ½À࣬ÆäËûµÄ·­ÒëÓ¦¸Ã±È½Ï¼òµ¥¡£
³ÕÃÔ¿ÆÑÐ
9Â¥2010-11-04 08:41:58
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ mjjnj µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 368»¯Ñ§Çóµ÷¼Á +13 wwwwabcde 2026-04-07 14/700 2026-04-09 14:47 by heaven_jay
[¿¼ÑÐ] ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£© +13 ÏàÐűػá¹ââÍòÕ 2026-04-06 16/800 2026-04-09 13:54 by ÐìÁ¼°×ü´óÏÀ
[¿¼ÑÐ] 085404 293Çóµ÷¼Á +5 ÓÂÔ¶¿â°®314 2026-04-08 5/250 2026-04-09 13:10 by ÐÀϲ777
[¿¼ÑÐ] Ò»Ö¾Ô¸Öпƴó070300»¯Ñ§£¬314·ÖÇóµ÷¼Á +7 wakeluofu 2026-04-09 7/350 2026-04-09 10:50 by ÈýÆßÆßÏëÉϰ¶
[¿¼ÑÐ] ²ÄÁÏ»¯¹¤×Ü·Ö334Çóµ÷¼Á +11 Riot2025 2026-04-08 11/550 2026-04-09 09:44 by gong120082
[¿¼ÑÐ] Ò»Ö¾Ô¸¼ª´ó»¯Ñ§327Çóµ÷¼Á +12 ÍõÍõ°×ʯ 2026-04-06 13/650 2026-04-08 16:05 by luoyongfeng
[¿¼ÑÐ] 277Çóµ÷¼Á +4 ¿¼Ñе÷¼Álxh 2026-04-06 6/300 2026-04-08 10:40 by ÄæË®³Ë·ç
[¿¼ÑÐ] 323Çóµ÷¼Á +3 ÁÖzlu 2026-04-07 4/200 2026-04-07 23:21 by lbsjt
[¿¼ÑÐ] 315Çóµ÷¼Á +17 СÑòСÑò_ 2026-04-02 18/900 2026-04-07 22:01 by lijunpoly
[¿¼ÑÐ] 336²ÄÁÏÓ뻯¹¤085600Çóµ÷¼Á +19 Ë®ÐǼÇinfp 2026-04-05 22/1100 2026-04-07 21:11 by yongzhesheng
[¿¼ÑÐ] 306Çóµ÷¼Á +3 15287505595 2026-04-03 3/150 2026-04-07 18:08 by À¶ÔÆË¼Óê
[¿¼ÑÐ] ¿¼Ñе÷¼Á +7 15615482637 2026-04-04 7/350 2026-04-06 22:56 by chenzhimin
[¿¼ÑÐ] 297·Ö083200ÇóÖú +9 aekx 2026-04-05 9/450 2026-04-06 20:57 by flysky1234
[¿¼ÑÐ] 362Çóµ÷¼ÁÒ»Ö¾Ô¸ÖйúʯÓÍ´óѧ +4 ÎÒÒª¿¼´ó 2026-04-06 6/300 2026-04-06 14:11 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] Çóµ÷¼Á +11 xzghyuj 2026-04-04 11/550 2026-04-06 11:49 by lijunpoly
[¿¼ÑÐ] ²ÄÁÏר˶(0856) 339·ÖÇóµ÷¼Á +10 ¹þ¹þ¹þ¶ì¹þ¹þ¹þ 2026-04-04 10/500 2026-04-05 18:51 by À¶ÔÆË¼Óê
[¿¼ÑÐ] ¹¤¿Æ277·ÖÇóµ÷¼Á²ÄÁÏ +8 ÉÏÁËÉÏÁËÉÏŶ 2026-04-05 9/450 2026-04-05 13:05 by wwytracy
[¿¼ÑÐ] ±¾¿Æ985£¬×¨Òµ0812·Ö336Çóµ÷¼Á +4 ĪĪºÜÐÐ 2026-04-03 4/200 2026-04-03 21:31 by zhq0425
[¿¼ÑÐ] Êý¶þÓ¢¶þ348Çóµ÷¼Á +4 hxdzj1 2026-04-03 5/250 2026-04-03 21:25 by zhq0425
[¿¼ÑÐ] 294Çóµ÷¼Á +6 Grey_Ey 2026-04-03 6/300 2026-04-03 20:46 by ÐÀϲ777
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û